0001209191-20-055492.txt : 20201021
0001209191-20-055492.hdr.sgml : 20201021
20201021173240
ACCESSION NUMBER: 0001209191-20-055492
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201019
FILED AS OF DATE: 20201021
DATE AS OF CHANGE: 20201021
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Greenberg Norman Michael
CENTRAL INDEX KEY: 0001773750
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38935
FILM NUMBER: 201251196
MAIL ADDRESS:
STREET 1: 500 SAGINAW DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Atreca, Inc.
CENTRAL INDEX KEY: 0001532346
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273723255
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 450 EAST JAMIE COURT
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-595-2595
MAIL ADDRESS:
STREET 1: 450 EAST JAMIE COURT
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-19
0
0001532346
Atreca, Inc.
BCEL
0001773750
Greenberg Norman Michael
C/O ATRECA, INC., 450 EAST JAMIE COURT
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Scientific Officer
Class A Common Stock
2020-10-19
4
M
0
500
4.56
A
500
D
Class A Common Stock
2020-10-19
4
S
0
500
15.1238
D
0
D
Stock Option (right to buy)
4.56
2020-10-19
4
M
0
500
0.00
D
2026-05-09
Class A Common Stock
500
21429
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.19, inclusive. The reporting person undertakes to provide to Atreca, Inc., any security holder of Atreca, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
1/4 of the Option vested on 5/2/2017 and 1/48 of the Option vests in equal monthly installments as measured from 5/2/2017. The shares subject to this option are early exercisable, subject to the Issuer's right to repurchase. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.
/s/ Herbert Cross, attorney-in-fact
2020-10-21